GH — what changed in the latest 10-Q
A section-by-section comparison of GH's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-07-30 vs the prior 10-Q · 2026-05-07
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +33 | −21 | ~13 | 29 |
| Market risk (Item 3) | Text added/removed | +1 | −2 | ~1 | 1 |
| Controls & procedures | Text added/removed | 0 | 0 | ~1 | 2 |
| Legal proceedings | No paragraph-level changes | 0 | 0 | 0 | 1 |
| Risk factors | No material changes reported (points to the 10-K) | — | — | — | — |
| Other information | Text added/removed | +1 | 0 | ~1 | 3 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-07-30
Total revenue was $335.0 million for the three months ended June 30, 2026, compared to $232.1 million for the three months ended June 30, 2025, an increase of $102.9 million, or 44%.
Oncology revenue was $219.1 million for the three months ended June 30, 2026, compared to $158.7 million for the three months ended June 30, 2025, an increase of $60.4 million, or 38%. This increase was driven primarily by an increase in oncology test volume to approximately 104,000 for the three mo…
Biopharma and data revenue was $60.9 million for the three months ended June 30, 2026, compared to $56.0 million for the three months ended June 30, 2025, an increase of $4.9 million, or 9%. This increase was driven primarily by the achievement of certain milestones within our companion diagnostic d…
Screening revenue was $52.9 million for the three months ended June 30, 2026, compared to $14.8 million for the three months ended June 30, 2025, an increase of $38.1 million, or 257%. The increase was driven primarily by an increase in our Shield screening test volume to approximately 66,000 for th…
Cost of revenue was $115.9 million for the three months ended June 30, 2026, compared to $81.2 million for the three months ended June 30, 2025, an increase of $34.7 million, or 43%. This increase in cost of revenue was driven primarily by an increase in sample volume, partially offset by reduced co…
Text removed vs the prior filing · source: 10-Q · 2026-05-07
Comparison of the Three Months Ended March 31, 2026 and 2025
Total revenue was $301.7 million for the three months ended March 31, 2026, compared to $203.5 million for the three months ended March 31, 2025, an increase of $98.2 million, or 48%.
Oncology revenue was $205.0 million for the three months ended March 31, 2026, compared to $150.6 million for the three months ended March 31, 2025, an increase of $54.4 million, or 36%. This increase was driven primarily by an increase in oncology test volume to approximately 86,000 for the three m…
Biopharma and data revenue was $53.0 million for the three months ended March 31, 2026, compared to $45.4 million for the three months ended March 31, 2025, an increase of $7.6 million, or 17%. This increase was driven primarily by the achievement of certain milestones within our companion diagnosti…
Screening revenue was $41.6 million for the three months ended March 31, 2026, compared to $5.7 million for the three months ended March 31, 2025, an increase of $35.9 million, or 633%. The increase was driven primarily by an increase in our Shield screening test volume to approximately 44,000 for t…
Market risk (Item 3)
Text added vs the prior filing · source: 10-Q · 2026-07-30
The majority of our revenue is generated in the United States. Through June 30, 2026, we have generated an insignificant amount of revenue denominated in foreign currencies. As we expand our presence in the international market, our results of operations and cash flows are expected to increasingly b…
Text removed vs the prior filing · source: 10-Q · 2026-05-07
The majority of our revenue is generated in the United States. Through March 31, 2026, we have generated an insignificant amount of revenue denominated in foreign currencies. As we expand our presence in the international
market, our results of operations and cash flows are expected to increasingly be subject to fluctuations due to changes in foreign currency exchange rates and may be adversely affected in the future due to changes in foreign exchange rates. As of March 31, 2026, the effect of a hypothetical 10% chan…
Other information
Text added vs the prior filing · source: 10-Q · 2026-07-30
(2)The 10b5-1 trading plan provides for the sale of 50% of an indeterminable number of shares of our common stock underlying certain restricted stock unit awards that will vest during the duration of the trading arrangement.
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice